The Italian Pharmacovigilance Program: An Observational Study of Adverse Effects of Natalizumab in Multiple Sclerosis Therapy
The Italian Pharmacovigilance Program: An Observational Study of Adverse Effects of Natalizumab in Multiple Sclerosis Therapy Giacoppo S, Ruscica M, Grimaldi LM, Bramanti P, The following content is accessible for members only, please sign in.